Pediatric nephrology (Berlin, Germany)
Evaluation of ravulizumab trough levels in pediatric complement-mediated hemolytic uremic syndrome in remission.
Samara M Mendez Nunez, Samantha Brokenshire, Poyyapakkam Srivaths, Joseph Angelo, Shweta Shah, Mini Michael
Published: 202610.1007/s00467-025-07113-5
Abstract
BACKGROUND: Ravulizumab drug monitoring has not been explored for maintenance therapy in patients with complement-mediated (atypical) hemolytic uremic syndrome (aHUS). Phase III trials suggest the standard dosing regimen provides troughs about threef…
Preview only. Read the full abstract at the source